Should scientific innovation be managed?

Drug Discovery Today

Volumn 7, Issue 18, 2002, Pages 941-945

  Schmid, Esther F ^a   Smith, Dennis A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR;

DRUG DETERMINATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SCREENING; LABORATORY; PERSONNEL MANAGEMENT; REVIEW;

DRUG INDUSTRY; PHARMACOLOGY; RESEARCH; SCIENCE;

EID: 0037107045     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02404-2     Document Type: Review

References (15)

1. Johnson G. What place for R&D in tomorrow's drug industry? Drug Discov. Today. 1:1996;117-121.
2. Hughes D. Predicting the future for R&D - science or art? Drug Discov. Today. 3:1998;487-489.
3. MacInnes R., et al. New chemical entity output of the international pharmaceutical industry from 1970 to 1992. Clin. Pharmacol. Ther. 56:1994;39-49.
4. Halliday, R.G. et al. (1999). Profile of the pharmaceutical industry from 1998 to 2000, R&D expenditure and staffing. CMR International (available online at: http://www.cmr.org/1999_4.html
5. Arlington A., Peakman T. Assessing the impact of current trends in genomics on the future of pharmaceutical R&D. Drug Discov. Today. 6:2001;161-162.
6. Love B. Virtual pharmaceutical R&D: a strategy for the millenium? Pharmaceut. Sci. Technol. Today. 1:1998;89-90.
7. Davidson A. Investment status of biopharmaceuticals. Drug Discov. Today. 3:1998;391-392.
8. Drews J. Innovation deficit revisited: reflections on the productivity of pharmaceutical R&D. Drug Discov. Today. 3:1998;491-494.
9. Duncan W.A.M. Some decisions in the development of cimetidine. Drug Dev. Res. 30:1993;18-23.
10. Hansen R.W. Chien R.I., et al. The Pharmaceutical Development Process: Estimates of Current Development Costs and Times and the Effect of Regulatory Changes (Issues in Pharmaceutical Economics). 1979;Lexington Books.
11. Austin A. Passion versus fear as the emotion driving scientists. Drug Discov. Today. 3:1998;419-422.
12. Kirton M.J. Adaptors and Innovators: a description and a measure. J. Appl. Psychol. 61:1976;622-629.
13. Kirton M.J. Adaptors and Innovators: cognitive style and personality. Isaksen S.G., Frontiers of Creativity Research: Beyond the Basics. 1987;282-304 Bearly Limited, New York.
14. Dale M. Learning organizations. Mabey C., Iles P., Managing Learning. 1994;The Open University, Thomson Business Press.
15. Stork D. Not all differences are created equal: Not all should be managed the same: the diversity challenge in pharmaceutical R&D. Drug Dev. Res. 43:1998;174-181.